A Correlation Evaluation Between the Peripheral Blood Index and the Prognosis of Advanced Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab

References

• Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649–658.e642. doi:10.1053/j.gastro.2022.05.054
   PubMed Web of Science ®Google Scholar
• Waters JK, Reznik SI. Update on management of squamous cell esophageal cancer. Curr Oncol Rep. 2022;24(3):375–385. doi:10.1007/s11912-021-01153-4
   PubMed Web of Science ®Google Scholar
• Weidenbaum C, Gibson MK. Approach to localized squamous cell cancer of the esophagus. Curr Treat Options Oncol. 2022;23(10):1370–1387. doi:10.1007/s11864-022-01003-w
   PubMed Web of Science ®Google Scholar
• Li Q, Liu T, Ding Z. Neoadjuvant immunotherapy for resectable esophageal cancer: a review. Front Immunol. 2022;13:1051841. doi:10.3389/fimmu.2022.1051841
   PubMed Web of Science ®Google Scholar
• Kelly RJ. Emerging multimodality approaches to treat localized esophageal cancer. J Natl Compr Canc Netw. 2019;17(8):1009–1014. doi:10.6004/jnccn.2019.7337
   PubMed Web of Science ®Google Scholar
• Hong Y, Ding ZY. PD-1 inhibitors in the advanced esophageal cancer. Front Pharmacol. 2019;10:1418. doi:10.3389/fphar.2019.01418
   PubMed Web of Science ®Google Scholar
• da Silva LL, Aguiar PN, Park R, Edelman Saul E, Haaland B, de Lima Lopes G. Comparative efficacy and safety of programmed Death-1 pathway inhibitors in advanced gastroesophageal cancers: a systematic review and network meta-analysis of Phase III clinical trials. Cancers. 2021;13(11):2614. doi:10.3390/cancers13112614
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Banchereau R, Leng N, Zill O, et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021;12(1):3969. doi:10.1038/s41467-021-24112-w
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi:10.1038/s41571-021-00473-5
   PubMed Web of Science ®Google Scholar
• Zhao Q, Bi Y, Xue J, Liu Y, Zhu J, Qin S. Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis. Ann Translat Med. 2022;10(13):744. doi:10.21037/atm-22-2669
   PubMed Web of Science ®Google Scholar
• Hwang M, Canzoniero JV, Rosner S, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. doi:10.1136/jitc-2022-004688
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi:10.1038/s41392-021-00658-5
   PubMed Web of Science ®Google Scholar
• Chen Y, Wen S, Xia J, et al. Association of dynamic changes in peripheral blood indexes with response to PD-1 inhibitor-based combination therapy and survival among patients with advanced non-small cell lung cancer. Front Immunol. 2021;12:672271. doi:10.3389/fimmu.2021.672271
   PubMed Web of Science ®Google Scholar
• Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. 2021;273(3):532–541. doi:10.1097/SLA.0000000000003370
   PubMed Web of Science ®Google Scholar
• Gou M, Qian N, Zhang Y, et al. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol. 2022;13:950868. doi:10.3389/fimmu.2022.950868
   PubMed Web of Science ®Google Scholar
• Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Can Cell Inter. 2021;21(1):356. doi:10.1186/s12935-021-02072-x
   PubMed Web of Science ®Google Scholar
• Ouyang H, Xiao B, Huang Y, Wang Z. Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy. Int Immunopharmacol. 2023;123:110703. doi:10.1016/j.intimp.2023.110703
   PubMed Web of Science ®Google Scholar
• Claps G, Faouzi S, Quidville V, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19(12):749–762. doi:10.1038/s41571-022-00686-2
   PubMed Web of Science ®Google Scholar
• Yan Y, Feng X, Li C, Lerut T, Li H. Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy. Chinese Med J. 2022;135(18):2143–2156. doi:10.1097/CM9.0000000000002371
   PubMed Web of Science ®Google Scholar
• Sihag S, Ku GY, Tan KS, et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thoracic Cardiovasc Surg. 2021;161(3):836–843.e831. doi:10.1016/j.jtcvs.2020.11.106
   PubMedGoogle Scholar
• Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol. 2022;13:1020290. doi:10.3389/fimmu.2022.1020290
   PubMedGoogle Scholar
• Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353–1367. doi:10.1158/2159-8290.CD-20-1312
   PubMed Web of Science ®Google Scholar
• Rimini M, Casadei-Gardini A, Ravaioli A, et al. Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the bagnacavallo population study. J Clin Med. 2020;9(4):1177. doi:10.3390/jcm9041177
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu D, Song H, et al. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ open. 2021;11(9):e048324. doi:10.1136/bmjopen-2020-048324
   PubMed Web of Science ®Google Scholar
• Liu J, Gao D, Li J, Hu G, Liu J, Liu D. The predictive value of systemic inflammatory factors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab. Onco Targets Ther. 2022;15:1161–1170. doi:10.2147/OTT.S382967
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503. doi:10.1038/s41568-020-0281-y
   PubMed Web of Science ®Google Scholar
• Zhang X, Gari A, Li M, et al. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022;20(1):61. doi:10.1186/s12967-022-03252-7
   PubMed Web of Science ®Google Scholar
• Ma R, Yuan D, Mo C, et al. Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer. Sci Rep. 2023;13(1):6080. doi:10.1038/s41598-023-33038-w
   PubMed Web of Science ®Google Scholar
• Miholjcic TBS, Halse H, Bonvalet M, et al. Rationale for LDH-targeted cancer immunotherapy. Eur J Cancer. 2023;181:166–178. doi:10.1016/j.ejca.2022.11.032
   PubMed Web of Science ®Google Scholar
• Van Wilpe S, Koornstra R, Den Brok M, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020;9(1):1731942. doi:10.1080/2162402X.2020.1731942
   PubMed Web of Science ®Google Scholar
• Cheng M, Li G, Liu Z, Yang Q, Jiang Y. Pretreatment neutrophil-to-lymphocyte ratio and lactate dehydrogenase predict the prognosis of metastatic cervical cancer treated with combination immunotherapy. J Oncol. 2022;2022:1828473. doi:10.1155/2022/1828473
   PubMed Web of Science ®Google Scholar
• Dercle L, Ammari S, Roblin E, et al. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. Eur J Cancer. 2022;177:80–93. doi:10.1016/j.ejca.2022.08.034
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang B, Chen X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thoracic Cancer. 2019;10(6):1395–1401. doi:10.1111/1759-7714.13083
   PubMed Web of Science ®Google Scholar
• Li Y, Wang K, Zhao E, et al. Prognostic value of lactate dehydrogenase in second-line immunotherapy for advanced esophageal squamous cell carcinoma. Pathol Oncol Res. 2022;28:1610245. doi:10.3389/pore.2022.1610245
   PubMed Web of Science ®Google Scholar
• Patel A, West HJ. What does my stage of cancer mean? JAMA Oncol. 2020;6(8):1308. doi:10.1001/jamaoncol.2020.1592
   PubMed Web of Science ®Google Scholar
• Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672. doi:10.1186/s12885-019-5903-y
   PubMed Web of Science ®Google Scholar